Extract
Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 in Wuhan, China. Since then, it has spread globally, resulting in the ongoing COVID-19 pandemic, causing more than 580 million documented cases. While most of these cases are characterised by a mild course of disease, a considerable percentage of SARS-CoV-2 infections evoke severe lung involvement, and ultimately lead to acute respiratory distress syndrome (ARDS). The latter has been causative for most of the >6 million documented deaths between December 2019 and September 2022. Despite the availability of effective vaccines and antivirals, COVID-19 ARDS will thus keep on challenging healthcare workers around the globe.
Abstract
Adopting a personalised therapy for patients with acute respiratory distress syndrome (ARDS) may improve outcomes https://bit.ly/3EqZupE
Footnotes
Conflict of interest: M. Witzenrath reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Stiftung, Capnetz Stiftung, International Max Planck Research School, Actelion, Bayer Health Care, Biotest and Boehringer Ingelheim; consulting fees from Noxxon, Pantherna, Vaxxilon, Aptarion, GlaxoSmithKline, Sinoxa and Biotest; lecture honoraria from AstraZeneca, Berlin Chemie, Chiesi, Novartis, Teva, Actelion, Boehringer Ingelheim, GlaxoSmithKline, Biotest and Bayer Health Care; and has patents EPO 12181535.1 (IL-27 for modulation of immune response in acute lung injury), WO/2010/094491 (Means for inhibiting the expression of Ang-2), DE 102020116249.9 (Camostat/Niclosamide cotreatment in SARS-CoV-2 infected human lung cells) and PCT/EP2021/075627 (New medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators) issued; outside the submitted work. T. Welte reports grants from German Ministry of Research and Education.
- Received September 21, 2022.
- Accepted October 3, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org